A swinepox virus (SPV) was used as a vector to express truncated muramidase-released protein (MRP) of S. suis type 2 (SS2), designated rSPV-MRP (Huang et al., 2012).
g. Immunization Route
Intramuscular injection (i.m.)
h.
Mouse Response
Vaccination Protocol:
Mice were immunized intramuscularly with rSPV-MRP, SS2 inactive vaccine (positive control), wild-type SPV (negative control) and PBS (blank control) (Huang et al., 2012).
Vaccine Immune Response Type:
VO_0003057
Challenge Protocol:
All CD1 mice were challenged with a lethal dose or a sublethal dose of SS2 highly virulent strain ZY05719 (Huang et al., 2012).
Efficacy:
SS2 inactive vaccine protected all mice, immunization with rSPV-MRP resulted in 60% survival and protected mice against a lethal dose of the highly virulent SS2 strain, compared with the negative control (Huang et al., 2012).
III. References
1. Huang et al., 2012: Huang D, Zhu H, Lin H, Xu J, Lu C. First insights into the protective effects of a recombinant swinepox virus expressing truncated MRP of Streptococcus suis type 2 in mice. Berliner und Munchener tierarztliche Wochenschrift. 2012; 125(3-4); 144-152. [PubMed: 22515033].
